PHARMACY

Google.org to expand Google Flu Trends tracking

BY Michael Johnsen

MOUNTAIN VIEW, Calif. Google.org on Tuesday announced on its blog site that it is expanding its Google Flu Trends tracking capabilities from the macro to the micro.

“We’ve been chatting with public health officials about new ways we can help people understand the spread of flu during this unusual time and today we’re excited to bring city level flu estimates to 121 cities in the United States,” the company wrote in its blog.

The city level estimates are “experimental,” the company cautioned, meaning they haven’t been validated against official data. However, the estimates are made in a similar manner to its U.S. national estimates, which have been validated.

In contrast to the unusually early spike of flu activity this October, Google Flu Trends is currently showing a low level of activity in the United States.

Google Flu Trends helps estimate flu trends in real time by tracking the popularity of certain Google search queries.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

New report projects sales of Parkinson’s disease drug will reach $500 million

BY Alaric DeArment

WALTHAM, Mass. A drug made by Boehringer Ingelheim for treating Parkinson’s disease could have sales of up to half a billion dollars, according to a new analysis.

According to a report released Tuesday by market research firm Decision Resources, BI’s extended-release formulation of pramipexole will have peak-year sales of between $250 million and $500 million in major pharmaceutical markets. The drug was launched in Europe in 2009 and is expected to enter the market in the United States this year.

In the beginning, according to the report, launches of generic formulations of the immediate-release version of pramipexole and competition from GlaxoSmithKline’s and SkyePharma’s Requip XL (ropinirole CR) and generic versions of immediate-release Requip will put a damper on sales of pramipexole ER. However, physician familiarity with the drug and preference among physicians and patients for once-daily dosing will cause a “significant” increase in sales.

“Given physician comfort in prescribing pramipexole for Parkinson’s disease and the convenience of once-daily dosing that it would offer, we expect that pramipexole ER will take much of pramipexole IR’s patient share,” Decision Resources analyst Sami Fam said. “In the short term, we expect pramipexole ER will lose some patient share to ropinirole CR given that ropinirole CR was the first of the two agents to launch. But over the long term, physicians’ slight preference for pramipexole over ropinirole should help to boost pramipexole ER’s uptake.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Report: Weis Markets acquires local Medicine Shoppe pharmacy

BY Michael Johnsen

SUNBURY, Pa. Weis recently acquired a Medicine Shoppe pharmacy in the Binghamton, N.Y., market, local newscaster News Channel 34 (owned by Newport Television) reported early Tuesday morning.

Weis Markets currently has 120 in-store pharmacies at other locations and is considering more at its Broome County locations, the report noted.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?